News & Articles

Avacta provides recent updates on the performance of its antigen lateral flow tests with the Omicron variant

The clinical data for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test demonstrated 100% sensitivity

The test offers 98.0% clinical sensitivity for samples with PCR Ct values up to 31

Avacta’s AffiDX SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus

Partnership aims to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing

Affimer-based research assay launched alongside performance data published by Bruker

Following successful evaluation by The Liverpool School of Tropical Medicine, the ELISA test will now be made available for COVID-19 researchers

Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva

Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva

Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases

Avacta to begin clinical validation of the high-throughput COVID-19 laboratory test in collaboration with the UK government CONDOR program

Partnership to evaluate the use of Affimer reagents to detect the coronavirus using novel sensors

Highly specific prototype test detects the virus spike protein at clinically relevant concentrations

Partnership to develop and manufacture a rapid test for the COVID-19 coronavirus infection for population screening